Advertisement
In a case report published online April 11 in the Journal of Diabetes Investigation

Rapid-Onset Diabetes Described With Anti-PD-1 Treatment

0
Case report of rapid-onset insulin-dependent diabetes with anti-programmed cell death 1 therapy
When it comes to dealing with illness

Many Americans Turn to ‘Laying on of Hands’ to Promote Healing

0
And, nearly nine out of 10 have asked for divine intervention for someone else
Higher intake of saturated fat from foods is associated with more aggressive prostate cancer

Diet Can Impact Aggressiveness of Prostate Cancer

0
Researchers also suggests that statins may help counteract harmful effect of fatty foods
The incidence of transfusion-transmitted malaria can be reduced with use of a whole blood pathogen-reduction system

Pathogen Reduction System Prevents Malaria Via Transfusion

0
Plasmodium inactivation in whole blood reduces incidence of transfusion-transmitted malaria
Electronic health records may be impairing the physician-patient relationship

A Doctor’s View: EHRs Impair Physician-Patient Relationship

0
Physician discusses impact of EHR on the physician-patient relationship
Doctors can be involved in developing new payment models for their practices

Physicians Can Get Involved in Developing Payment Models

0
New payment models relating to bone metastases, breast cancer developed by ASTRO
Treatment with aromatase inhibitors doesn't raise the risk of the most fatal cardiovascular disease events among breast cancer survivors

Aromatase Inhibitors Won’t Raise Odds of Most Fatal CVD Events

0
But there is a slightly increased risk of less serious cardiovascular issues
Anthracyclines are not related to "chemo brain

Anthracyclines May Not Trigger ‘Chemo Brain’

0
New research finds no link between the meds and survivors' cognitive function
Regular education can improve radiologists' performance in detection of breast cancer from mammography

Ongoing Education Betters Mammography Interpretation

0
Findings based upon radiologists' use of the Breast Reader Assessment Strategy program
Pembrolizumab is associated with an overall objective response rate of 33 percent in patients with advanced melanoma

Pembrolizumab Active in Patients With Advanced Melanoma

0
Overall response rate of 33 percent for total population, 45 percent among treatment naive